非相互/相互ALK易位是一线克唑替尼治疗ALK重排NSCLC的不良预测标志
该研究纳入150例NGS检测ALK重排的NSCLC患者,其中112例接受一线克唑替尼治疗。非相互/相互ALK易位检出率为18.7%,此类患者基线脑转移发生率更高(39.1% vs 13.4%,p=0.028),中位PFS显著缩短(6.1m vs 12.0m,p=0.001),多因素分析显示其为PFS更差的独立预测因素(p=0.0046)。
要点
- 非相互/相互ALK易位在ALK重排NSCLC中占18.7%。
- 此类患者一线克唑替尼中位PFS仅6.1个月,显著短于3'-ALK融合者。
- 基线脑转移发生率更高(39.1% vs 13.4%),为独立不良预测因素。
核心结论
- 非相互/相互ALK易位预示一线克唑替尼PFS更差且基线脑转移可能性更高。
研究设计与样本
- 回顾性研究纳入2014年3月至2018年7月湖南省肿瘤医院150例NGS检测ALK重排NSCLC患者,其中112例评估一线克唑替尼疗效。
主要发现
- 150例中非相互/相互易位占18.7%(28/150),单纯3'-ALK融合占81.3%(122/150)。
- 112例接受一线克唑替尼者中89例为单纯3'-ALK融合(79例EML4-ALK,10例非EML4-ALK),23例为非相互/相互ALK易位。
- 非相互/相互易位组基线脑转移发生率39.1% vs 13.4%(p=0.028)。
- 非相互/相互易位组中位PFS 6.1m vs 单纯3'-ALK融合12.0m(p=0.001),vs 单纯EML4-ALK融合12.6m(p=0.001)。
- 多因素分析显示非相互/相互ALK易位是PFS更差的独立预测因素(p=0.0046)。
临床怎么用
- 对NGS检出非相互/相互ALK易位的NSCLC患者,一线克唑替尼需警惕原发耐药和脑转移风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: During nonreciprocal/reciprocal translocation process, 5'-anaplastic lymphoma kinase (ALK) sometimes gets retained in the genome and is detectable by next-generation sequencing; however, no study has investigated its clinical significance. Our study aimed to assess the impact of harboring 5'-ALK on the efficacy of crizotinib. METHODS: A total of 150 patients with next-generation sequencing-identified ALK-rearranged NSCLC from March 2014 to July 2018 at the Hunan Cancer Hospital were enrolled in this study. The efficacy of crizotinib as first-line therapy was evaluated in 112 patients according to the retention of 5'-ALK. RESULTS: Among the 150 patients with NSCLC, nonreciprocal/reciprocal translocation was detected in 18.7% (28 of 150), and 3'-ALK fusion alone was detected in 81.3% (122 of 150). Among the 112 patients who received first-line crizotinib, 89 had 3'-ALK fusion alone (79 echinoderm microtubule associated protein-like 4 [EML4]-ALK and 10 non-EML4-ALK), and 23 had nonreciprocal/reciprocal ALK translocation. Among the patients with nonreciprocal/reciprocal ALK translocation, three patients harbored dual concurrent 3'-ALK fusions. Patients with nonreciprocal/reciprocal ALK translocation had higher incidence of brain metastasis at baseline than those with 3'-ALK fusion alone (39.1% versus 13.4%, p = 0.028). Crizotinib-treated patients with nonreciprocal/reciprocal ALK translocation had significantly shorter median progression-free survival (PFS) compared with patients carrying 3'-ALK fusion alone (6.1 m versus 12.0 m, p = 0.001) or with EML4-ALK fusion alone (6.1 m versus 12.6 m, p = 0.001). Multivariate analysis revealed that harboring nonreciprocal/reciprocal ALK translocation was an independent predictor of worse PFS for crizotinib-treated ALK-rearranged NSCLC (p = 0.0046). CONCLUSIONS: Presence of nonreciprocal/reciprocal ALK translocation was predictive for worse PFS and greater likelihood of baseline brain metastases in patients with ALK-rearranged NSCLC who received first-line crizotinib.
引用
- Zhang Y, Zeng L, Zhou C, et al. Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. J Thorac Oncol. 2020. PMID: 32112982. doi:10.1016/j.jtho.2020.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。